Significantly, more patients with PTPN2 deletion than PTPN2 wild-type T-ALL had other accompanying disorders: NUP214-ABL gene fusion (21 vs. 7%), IL7R/JAK-STAT (74 vs. 41%), NOTCH1/FBXW7 (85 vs. 63%), and PHF6 (95 vs. 41%) mutations. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.